Drug industry productivity is finally improving after years of research disappointment, as drugmakers shift their focus from mass markets to making medicines for rarer, under-treated diseases.
Data from Thomson Reuters published on Tuesday showed more new drugs are reaching the market and that the industry has been enjoying higher success rates in the costly final stage of clinical development.
The number of innovative medicines, or new molecular entities, launched globally in 2011 hit a 10-year high of 31, up from 21 in 2010.
Last year's entrants included significant advances, such as new treatments from Roche and Bristol-Myers Squibb for melanoma, the first new drug for lupus in half a century from GlaxoSmithKline, and two new hepatitis C drugs from Merck and Vertex Pharmaceuticals. . .View Full Article